The U.S. Food and Drug Administration (FDA) has issued a notice to manufacturers of a drug to treat epilepsy, a drug that is being touted as a possible cure for people with the disorder.
The FDA has been working to develop the drug, a generic version of the drug called GlaxoSmithKline’s Epidiolex.
It said Glaxos has agreed to sell the drug to an independent developer of a generic, but it is not clear if the manufacturer will get to sell its drug to consumers or whether it will be sold directly to them.
As of Thursday, the company was distributing its drug, called Zoloft, through distributors in the United States and Europe.
The generic version, called Epidione, is made by a different company called Merck.
The drug was first approved in 2003 for treatment of seizures in adults with epilepsy and is the first FDA-approved drug to be used in adults without epilepsy.
It is the second drug to use a brand name, the first being a drug called Zosort, that was approved for the treatment of children.
Both drugs are approved by the Food and Drugs Administration (FDNY).
The FDA said Glixo has been using the name Epidine in marketing materials since the drug’s development, which began in 2014.
The agency did not provide a timeline for when Epidison would be available in the U.K. and other countries.